JO
OSIR

John Overdeck’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

John Overdeck’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-78,148
Closed -$446K – 3501
2016
Q1 		$446K Buy
+78,148
New +$546K ﹤0.01% 2133

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

John Overdeck's OSIR Position: Q2 2016 in Review

John Overdeck sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2016, closing a stake of 78,148 shares — an estimated $446K sold.

John Overdeck first reported a position in OSIR in Q1 2016 and held it in 1 quarter. The position peaked at $446K in Q1 2016. 68 funds tracked by Wall St. Rank hold OSIR as of Q2 2016.

  • John Overdeck reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • John Overdeck sold 78,148 Osiris Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $446K.
  • John Overdeck first reported a position in Osiris Therapeutics, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • John Overdeck's Osiris Therapeutics, Inc. Common Stock position peaked at $446K in Q1 2016.
  • 68 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Two Sigma Investments's 13F filing for Q2 2016, filed 15 Aug 2016.